Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Written by
Armstrong AJ, Saad F, Phung, Dmuchowski C, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J.